In the Claims

Please cancel claims 3-4 and 9-10 and amend claims 1-2 as follows:

1. (Currently amended) A method of reducing the viability of leukemia cells in a mammal sensitive to a 1-(R) compound of formula (II):



(II)

wherein R^1 is lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, phenyl or benzyl, R^2, R^3, R^4 and R^5 are the same or different and are each hydrogen or lower alkyl; R^6 is hydrogen, lower alkyl, hydroxy, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro or halo, R^7 is hydrogen, lower alkyl or lower alkenyl; X is oxy; Y is carbonyl or (C_1-C_3)alkyl(CO), wherein each alkyl is substituted with 0-2 (C_1-C_4) alkyl, and Z is hydroxy, lower alkoxy, amino, lower alkylamino, di(lower)alkylamino or phenylamino;

comprising administering ~~from about 50 mg to about 5000 mg of~~ the (R)-compound of formula (II); or a salt thereof to a cancer patient afflicted with a leukemia so as to achieve a plasma level of the compound in the mammal of about 200 μM to 600 μM.

2. (Currently amended) A method of increasing the susceptibility of leukemia cells in a mammal to a chemotherapeutic agent comprising contacting the cells with ~~from about 50 mg to about 5000 mg of~~ a compound of formula (II):



(II)

wherein R^1 is lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, phenyl or benzyl, R^2, R^3, R^4 and R^5 are the same or different and are each hydrogen or lower alkyl; R^6 is hydrogen, lower alkyl, hydroxy, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro or halo, R^7 is hydrogen, lower alkyl or lower alkenyl; X is oxy; Y is carbonyl or (C_1-C_3)alkyl(CO), wherein each alkyl is substituted with 0-2 (C_1-C_4) alkyl, and Z is hydroxy, lower alkoxy, amino, lower alkylamino, di(lower)alkylamino or phenylamino; or a pharmaceutically acceptable salt thereof so as to achieve a blood plasma concentration of the compound in the mammal of about 200 μM to 600 μM.

Claims 3-4 (Cancelled).

5. (Previously Presented) The method of claim 1 wherein the compound of formula (II) is administered in a single dose.

6. (Previously Presented) The method of claim 2 wherein the compound of formula (II) is administered in a single dose.

7. (Previously Presented) The method of claim 1 wherein the compound of formula (II) is administered in divided doses.

8. (Previously Presented) The method of claim 2 wherein the compound of formula (II) is administered in divided doses.

Claims 9-10 (Cancelled).

11. (Original) The method of claim 1 wherein the leukemia is chronic lymphocytic leukemia.

12. (Original) The method of claim 2 wherein the leukemia is chronic lymphocytic leukemia.

13. (Previously Presented) The method of claim 1 wherein the mammal is a human.

14. (Previously Presented) The method of claim 2 wherein the mammal is a human.

15. (Cancelled).

16. (Original) The method of claim 1 wherein the compound of formula (II) or the salt thereof is administered orally.

17. (Original) The method of claim 2 wherein the compound of formula (II) or the salt thereof is administered orally.

18. (Original) The method of claim 1 wherein the compound of formula (II) is R(-)-etodolac.

19. (Original) The method of claim 2 wherein the compound of formula (II) is R(-)-etodolac.

20. (Cancelled).